Our data demonstrate that mifepristone, at concentrations beyond those used to achieve cytostasis has lethal activity triggering a caspase-associated apoptotic process in all six ovarian cancer cell lines studied regardless of their p53 genetic backgrounds and sensitivities to cisplatin. The gene discussed is TP53; the disease is ovarian cancer.